^
CANCER:

Non-Hodgkin’s Lymphoma





Show legend
Group by Gene:
Include preclinical:

BTK inhibitor
ibrutinib
zanubrutinib
pirtobrutinib
0
BTK inhibitor
orelabrutinib
acalabrutinib
M7583
TG-1701
JNJ-4681
CD20 inhibitor
rituximab
obinutuzumab
Rixathon (rituximab biosimilar)
1
CD20 inhibitor
rituximab-abbs
rituximab-pvvr
rituximab / hyaluronidase
ofatumumab
rituximab + obinutuzumab
rituximab-arrx
CD19-targeted CAR-T immunotherapy
lisocabtagene maraleucel
axicabtagene ciloleucel
tisagenlecleucel-T
brexucabtagene autoleucel
ALLO-501A
2
CD19-targeted CAR-T immunotherapy
CB-010
CTX110
relmacabtagene autoleucel
JCAR014
PZ01
ARI-0001
ISIKOK-19
3
PI3Kδ inhibitor
idelalisib
INCB50465
4
Bcl2 inhibitor, CD20 inhibitor
venetoclax + obinutuzumab
venetoclax + rituximab
5
CD52 inhibitor
alemtuzumab
chlorambucil
6
Alkylating agent
bendamustine RTD
cyclophosphamide
gemcitabine
fludarabine oral
7
DNA synthesis inhibitor
nelarabine
cisplatin
fludarabine IV
pembrolizumab
nivolumab
8
PD1 inhibitor
sintilimab
zimberelimab
geptanolimab
9
THF dehydrogenase inhibitor, Dihydrofolic acid reductase inhibitor
methotrexate
romidepsin
10
HDAC inhibitor
vorinostat
belinostat
CG-781
11
Proteasome inhibitor, CD20 inhibitor
rituximab + ixazomib
rituximab + bortezomib
CD20 inhibitor + zanubrutinib
obinutuzumab + acalabrutinib
ibrutinib + rituximab
12
BTK inhibitor, CD20 inhibitor
ibrutinib + obinutuzumab
rituximab + zanubrutinib
obinutuzumab + zanubrutinib
rituximab + acalabrutinib
13
Topoisomerase II inhibitor
pixantrone
etoposide IV
14
PI3Kδ inhibitor, CD20 inhibitor
rituximab + idelalisib
obinutuzumab + INCB50465
pembrolizumab + ibrutinib
15
PD1 inhibitor, BTK inhibitor
nivolumab + ibrutinib
tislelizumab + zanubrutinib
16
CD52 inhibitor, CD20 inhibitor
rituximab + alemtuzumab
17
mTOR inhibitor
everolimus
temsirolimus
ceritinib
18
ALK inhibitor
crizotinib
alectinib
19
Bcl2 inhibitor
venetoclax
APG-2575
20
Bcl2 inhibitor, BTK inhibitor
venetoclax + ibrutinib
ibrutinib + APG-2575
PD-L1 inhibitor
sugemalimab
21
PD-L1 inhibitor
atezolizumab
durvalumab
avelumab
22
PIK3CA inhibitor, PI3Kδ inhibitor
copanlisib
loncastuximab tesirine-lpyl
23
DNA replication inhibitor, CD19-targeted antibody-drug conjugate
IKS03
SGN-CD19B
tazemetostat
24
EZH2 inhibitor
CPI-169
SHR-2554
25
IL-2 stimulant
denileukin diftitox
26
Proteasome inhibitor
bortezomib
carfilzomib
27
XPO1 inhibitor
selinexor
28
Retinoid X receptor modulator
bexarotene oral
29
CCR4 receptor antagonist
mogamulizumab-kpkc
30
THF dehydrogenase inhibitor
pralatrexate
31
Purinergic receptor P1 agonist
cladribine
32
Protein synthesis inhibitor, Asparagine depleter
recombinant Erwinia asparaginase
33
DNA replication inhibitor
bendamustine
34
DNMT inhibitor
azacitidine oral
35
CXCL12 inhibitor, Farnesyl transferase inhibitor
tipifarnib
36
PIK3CA inhibitor, PI3Kδ inhibitor, CD20 inhibitor
rituximab + copanlisib
37
NK cell stimulant
IDP-023
38
SETD2 inhibitor
IPN60210
39
CD38 inhibitor
daratumumab
40
PD1 inhibitor, LAG-3 inhibitor
MGD013
41
JAK1 inhibitor
DZD4205
42
PD1 inhibitor, Survivin inhibitor
pembrolizumab + MVP-S
43
CDK9 inhibitor
SLS009
44
STAT3 protein degrader
KT-333
45
CD19-targeted CAR-T immunotherapy, BTK inhibitor
ibrutinib + lisocabtagene maraleucel
acalabrutinib + axicabtagene ciloleucel
46
CXCR4 antagonist, BTK inhibitor
ibrutinib + X4P-001
ibrutinib + BMS-936564
47
Bcl2 inhibitor, BTK inhibitor, CD20 inhibitor
venetoclax + ibrutinib + rituximab
venetoclax + obinutuzumab + zanubrutinib
48
Cereblon modulator, Pleiotropic pathway modifier
CC-122
49
PD1 inhibitor, CD19-targeted CAR-T immunotherapy
BRL-201
50
Topoisomerase II inhibitor, DNA synthesis inhibitor
gemcitabine + doxorubicin hydrochloride
51
ROR1 inhibitor, BTK inhibitor
ibrutinib + UC-961
52
CD3 agonist, ROR1 inhibitor
NVG-111
53
CD19-targeted CAR-T immunotherapy, BCMA-targeted CAR-T immunotherapy
GC012F
54
PARP inhibitor
fluzoparib
olaparib
55
CD47 inhibitor, CD20 inhibitor
rituximab + ALX148
IMM0306
56
SIRPA antagonist, CD20 inhibitor
rituximab + BMS-986351
57
Cereblon modulator, Pleiotropic pathway modifier, CD20 inhibitor
rituximab + CC-122
58
MDM2 inhibitor, BTK inhibitor
acalabrutinib + KRT-232
59
BET inhibitor
RG6146
INCB57643
60
CD70 inhibitor
ARGX-110
61
CD30-targeted CAR-T immunotherapy
TT11
CART-30
62
CD20-targeted CAR-T immunotherapy
MB-106
63
CXCR4 antagonist
X4P-001
64
CD137 agonist, CD20 inhibitor
rituximab + PF-05082566
R-CHOP
L / P-VIPD
BDR
EPOCH-R
ViPOR
R-DHAC + R-CHOP
R-DHAX + R-CHOP
R-CHOP + R-DHAP
R-Maxi-CHOP
Pola-R-CHP
BV-ICE
SMILE
EPOCH
DDGP
AspaMetDex
P-GEMOX
CHOEP
CHOP
GVD
RCP
RCD
CaRD
FCR
IRd
BR
OFAR
O-CVP
R-CDOP
R-CEPP
R-CEOP
65
Chemotherapy
R-GCVP
R-ESHAP
CEPP
CEOP
DHAP
DHAX
GDP
ICE
ESHAP
R-DHAP
GemOx
MINE
CARMEN
G-CHOP
R-GemOx
R-DHAX
VR-CAP
C-RICE
CHEP-BV
CMOP
PCR
RIVAC
RICE
R-GDP
R-CVAD
R-CVP
ZPR
BOVen
CVAD
CEOP-E
DICE
MATRix
66
T-lymphocyte cell therapy
T-lymphocyte cell therapy
67
Immunotherapy
Immunotherapy
68
CAR-T immunotherapy
CAR-T immunotherapy
69
USP47 inhibitor
USP47 inhibitor
70
CD20 inhibitor, Chemotherapy
CODOX-M + rituximab
71
BTK inhibitor, Chemotherapy
BR + ibrutinib
72
TNFα inhibitor, IL-12 inhibitor, IL-6 inhibitor
lenalidomide
73
TNFα inhibitor, Immunotherapy, IL-12 inhibitor, IL-6 inhibitor
Immunotherapy + lenalidomide
74
PI3Kδ inhibitor, Chemotherapy
BR + idelalisib
75
THF dehydrogenase inhibitor, Dihydrofolic acid reductase inhibitor, Chemotherapy
RIVAC + methotrexate
RICE + methotrexate
76
PI3Kγ inhibitor, PI3Kδ inhibitor
duvelisib
77
TNFα inhibitor, IL-12 inhibitor, IL-6 inhibitor, CD20 inhibitor
rituximab + lenalidomide
lenalidomide + obinutuzumab
78
CD20-targeted CAR-T immunotherapy, Bcl2 inhibitor
CD20-targeted CAR-T immunotherapy + venetoclax
brentuximab vedotin
79
CD30-targeted antibody-drug conjugate, Microtubule inhibitor
McSAF 02
TEQ102
80
EZH1 inhibitor, EZH2 inhibitor
valemetostat
DW91170
81
TNFα inhibitor, IL-12 inhibitor, IL-6 inhibitor, BTK inhibitor, CD20 inhibitor
ibrutinib + rituximab + lenalidomide
rituximab + lenalidomide + acalabrutinib
epcoritamab-bysp
mosunetuzumab-axgb
82
CD3 agonist, CD20 inhibitor
glofitamab-gxbm
EX103
REGN1979
83
JAK1 inhibitor, JAK2 inhibitor
ruxolitinib
84
Proteasome inhibitor, Chemotherapy
R-CHOP + bortezomib
85
ROS1 inhibitor, ALK inhibitor
lorlatinib
86
CD79b-targeted antibody-drug conjugate, Microtubule inhibitor, CD20 inhibitor
rituximab + polatuzumab vedotin-piiq
87
TNFα inhibitor, CD19 inhibitor, IL-12 inhibitor, IL-6 inhibitor
lenalidomide + tafasitamab-cxix
88
Topoisomerase II inhibitor, Alkylating agent
cyclophosphamide + etoposide IV
89
ALK inhibitor, EGFR inhibitor
brigatinib
90
Tubulin polymerization promoter, DNA synthesis inhibitor
carboplatin + gemcitabine
91
Ionizing radiation emitter, CD20 inhibitor
ibritumomab tiuxetan
rituximab + ibritumomab tiuxetan
92
PDGFR antagonist, mutant c-KIT inhibitor, CSF-1R inhibitor
avapritinib
93
Tubulin polymerization promoter, DNA synthesis inhibitor, CD20 inhibitor
carboplatin + gemcitabine + rituximab
94
Casein kinase I epsilon inhibitor, PI3Kδ inhibitor
umbralisib
95
Alkylating agent, DNA synthesis inhibitor
carmustine
96
Tubulin polymerization promoter, DNA synthesis inhibitor, DNA-directed DNAP inhibitor
carboplatin + cytarabine
97
THF dehydrogenase inhibitor, DNA synthesis inhibitor, Dihydrofolic acid reductase inhibitor, DNA-directed DNAP inhibitor
cytarabine + methotrexate
98
THF dehydrogenase inhibitor, DNA synthesis inhibitor, Dihydrofolic acid reductase inhibitor, DNA-directed DNAP inhibitor, Chemotherapy
R-CVAD + cytarabine + methotrexate
99
CD79b-targeted antibody-drug conjugate, Microtubule inhibitor
polatuzumab vedotin-piiq
ARC-02
100
DNMT inhibitor, Chemotherapy
CHOP + azacitidine oral
101
HDAC inhibitor, MAPK inhibitor, HDAC10 inhibitor, HDAC1 inhibitor, PI3K inhibitor, HDAC2 inhibitor, AKT inhibitor, HDAC3 inhibitor
chidamide
102
CD20-targeted CAR-T immunotherapy, CD19-targeted CAR-T immunotherapy
IMPT-314
JNJ-90014496
103
CD22-targeted antibody-drug conjugate, DNA replication inhibitor
inotuzumab ozogamicin
104
SIK3 inhibitor, PI3K inhibitor, PI3Kγ inhibitor, PI3Kδ inhibitor
RP6530
105
CD16 agonist, NK cell stimulant
FT516
106
Ionizing radiation emitter, DNA inhibitor
CLR 131
107
PD-L1 inhibitor, Bcl2 inhibitor, CD20 inhibitor
venetoclax + atezolizumab + obinutuzumab
108
TNFα inhibitor, IL-12 inhibitor, IL-6 inhibitor, BTK inhibitor
lenalidomide + zanubrutinib
109
Bcr-abl tyrosine kinase inhibitor, Src kinase inhibitor, c-KIT inhibitor, PDGFR β antagonist, EphA2 receptor antagonist
dasatinib
110
CD37-targeted antibody-drug conjugate, Microtubule inhibitor
AGS67E
111
TNFα inhibitor, IL-12 inhibitor, CD30-targeted antibody-drug conjugate, IL-6 inhibitor, Microtubule inhibitor, CD20 inhibitor
rituximab + lenalidomide + brentuximab vedotin
112
c-MET inhibitor, ROS1 inhibitor, ALK inhibitor
TQ-B3101
113
TNFα inhibitor, PD-L1 inhibitor, IL-12 inhibitor, IL-6 inhibitor
durvalumab + lenalidomide
114
CD30 inhibitor, CD16A agonist
AFM13
115
PDGFR inhibitor, Bcr-abl tyrosine kinase inhibitor, c-KIT inhibitor
imatinib
116
TNFα inhibitor, IL-12 inhibitor, CD3 agonist, IL-6 inhibitor, CD20 inhibitor
rituximab + lenalidomide + epcoritamab-bysp
lenalidomide + epcoritamab-bysp
117
CD19 inhibitor, CD3 agonist
A-319
CLN-978
118
HDAC inhibitor, MAPK inhibitor, HDAC10 inhibitor, HDAC1 inhibitor, PD1 inhibitor, PI3K inhibitor, HDAC2 inhibitor, AKT inhibitor, HDAC3 inhibitor
sintilimab + chidamide
119
CD22-targeted CAR-T immunotherapy, CD19-targeted CAR-T immunotherapy
CAR-T19 / CAR-T22 immunotherapy
120
HDAC inhibitor, PI3K inhibitor
CUDC-907
121
TNFα inhibitor, IL-12 inhibitor, PD1 inhibitor, IL-6 inhibitor, CD20 inhibitor
rituximab + lenalidomide + penpulimab
122
TNFα inhibitor, IL-12 inhibitor, IL-6 inhibitor, Bcl2 inhibitor, CD20 inhibitor
venetoclax + rituximab + lenalidomide
123
Bifunctional alkylating agent, THF dehydrogenase inhibitor, Topoisomerase II inhibitor, DNA synthesis inhibitor, Dihydrofolic acid reductase inhibitor, DNA-directed DNAP inhibitor
cytarabine + ifosfamide + etoposide IV + methotrexate
124
CD30-targeted antibody-drug conjugate, Microtubule inhibitor, CD20 inhibitor
rituximab + brentuximab vedotin
125
TNFα inhibitor, IL-1β inhibitor, IL-10 stimulant, NK cell stimulant, IL-6 inhibitor
pomalidomide
126
CD79b-targeted antibody-drug conjugate, Microtubule inhibitor, Bcl2 inhibitor
venetoclax + polatuzumab vedotin-piiq
127
CD20-targeted antibody-drug conjugate, Microtubule inhibitor
MRG001
128
LRRK2 inhibitor, ALK inhibitor
TAE-684
129
ALK inhibitor, PP2A inhibitor
crizotinib + LB-100
130
EIF-2 kinase modulator
BTM-3566
131
CD3 agonist, DNA replication inhibitor, CD20 inhibitor, CD19-targeted antibody-drug conjugate
loncastuximab tesirine-lpyl + IGM-2323
132
HDAC1 inhibitor, HDAC2b inhibitor
purinostat
133
CD22-targeted antibody-drug conjugate, Microtubule inhibitor
TRPH-222
134
CD38-targeted antibody-drug conjugate, Ionizing radiation emitter
Actinium-225 conjugated to daratumumab
135
Bcl2 inhibitor, Tubulin inhibitor, CD20 inhibitor
AR160
136
SLC1A5-targeted antibody-drug conjugate, DNA replication inhibitor
MEDI7247
137
DNA replication inhibitor, CD25-targeted antibody-drug conjugate
ADCT-301
138
CCR7-targeted antibody-drug conjugate, Microtubule inhibitor
JBH492
139
Alkylating agent, DNA repair enzyme inhibitor
LP-284
140
CD38 inhibitor, CD3 agonist, CD28 agonist
SAR442257
141
BTK degrader
ABBV-101
142
CD19 inhibitor, CD16A inhibitor, IL-15R stimulant, CD20 inhibitor
rituximab + FT596
143
Topoisomerase II inhibitor, HDAC inhibitor, MAPK inhibitor, HDAC10 inhibitor, HDAC1 inhibitor, PI3K inhibitor, HDAC2 inhibitor, AKT inhibitor, HDAC3 inhibitor
doxorubicin hydrochloride + chidamide
144
Electron transport complex I inhibitor
IACS-010759
145
Bcl2 inhibitor, SYK inhibitor
venetoclax + fostamatinib
146
Histone acetyltransferase activator
YF2
147
PIK3CA inhibitor, Bcl2 inhibitor, PI3Kδ inhibitor
venetoclax + copanlisib
148
PLK1 inhibitor
NBL-001
149
Apoptosis stimulant
arsenic trioxide
150
miR-155 inhibitor
MRG-106
151
Bcl2 inhibitor, Bcl-xL inhibitor, Bcl-w inhibitor
ABT 263
152
ROR1-targeted antibody-drug conjugate, Microtubule inhibitor
MK-2140
153
MALT1 protein inhibitor
ONO-7018
JNJ-6633
154
Lymphoid kinome inhibitor, Myeloid kinome inhibitor, BTK inhibitor, FLT3 inhibitor
CG-806
155
ROR1-targeted CAR-T immunotherapy
ONCT-808
156
MDM2 inhibitor, Bcl2 inhibitor
APG-115 + APG-2575
157
ACVR1 inhibitor, IRAK-1 inhibitor, CSF-1R inhibitor, JAK2 inhibitor, FLT3 inhibitor
pacritinib
158
PDK1 inhibitor, Bcl2 inhibitor
venetoclax + VRx-510
159
Casein kinase I epsilon inhibitor, PI3Kδ inhibitor, BTK inhibitor, CD20 inhibitor
umbralisib + ublituximab-xiiy + TG-1701
160
BET inhibitor, EZH2 inhibitor
CPI-169 + CPI-203
161
Kinase inhibitor
EUD-GK-001
162
Lymphoid kinome inhibitor, Bcl2 inhibitor, Myeloid kinome inhibitor, BTK inhibitor, FLT3 inhibitor
venetoclax + CG-806
163
PIM inhibitor, Bcl2 inhibitor, BTK inhibitor
venetoclax + ibrutinib + AZD1208
164
PLK4 inhibitor
CFI-400945
165
PLK1 inhibitor, PIK3CA inhibitor, PI3Kδ inhibitor
copanlisib + NBL-001
166
P21-activated kinase inhibitor
FRAX597 + PF-3758309
167
EZH2 inhibitor, Bcl2 inhibitor
venetoclax + tazemetostat
168
Multi-tyrosine kinase inhibitor
gilteritinib
169
MCL1 inhibitor
S63845
170
MCL1 inhibitor, Bcl2 inhibitor
venetoclax + S63845
171
CD52 inhibitor, BTK inhibitor
ibrutinib + alemtuzumab
172
CDK4 inhibitor, CDK6 inhibitor
palbociclib
173
HSP90 inhibitor
AUY922
174
DNA polymerase theta inhibitor
ART558
VP-006
175
γ-secretase inhibitor
Compound E
176
MALT1 protein inhibitor, BTK inhibitor
JNJ-6633 + JNJ-4681
177
DNA replication inhibitor, CD70-targeted antibody-drug conjugate
SGN-CD70A
178
XPO1 inhibitor, Bcl2 inhibitor
venetoclax + selinexor
179
DNA synthesis inhibitor, DNA-directed DNAP inhibitor
cytarabine
180
IKZF1 degrader, IKZF3 degrader
CFT7455
181
IKZF1 degrader, IKZF3 degrader, IRAK-4 degrader, CD20 inhibitor
rituximab + KT-413
182
ERK2 inhibitor, ERK1 inhibitor
ASN007
183
MEK inhibitor, ALK inhibitor
trametinib + crizotinib
184
HDAC inhibitor, EZH2 inhibitor, MAPK inhibitor, HDAC10 inhibitor, HDAC1 inhibitor, PI3K inhibitor, HDAC2 inhibitor, AKT inhibitor, HDAC3 inhibitor
chidamide + SHR-2554
185
BRD4 inhibitor, PI3K inhibitor, BTK inhibitor
SRX3262
186
MEK inhibitor, Bcl2 inhibitor
venetoclax + trametinib
187
PI3Kγ inhibitor, DNA PK inhibitor, Bcl2 inhibitor, PI3Kδ inhibitor
venetoclax + BR101801
188
IKZF1 degrader, IKZF3 degrader, IRAK-4 degrader, BTK inhibitor
BTK inhibitor + KT-413
189
IKZF1 degrader, IKZF3 degrader, IRAK-4 degrader
KT-413
No biomarker
TP53 wild-type
TP53 mutation
TP53 deletion
TP53 overexpression
TP53 A159V
TP53 mutation + Chr del(17p)
TP53 expression
ALK positive
ALK I1171N
ALK negative
ALK rearrangement
ALK fusion
MYC rearrangement + BCL2 rearrangement
MYC overexpression + BCL2 overexpression
BCL2 overexpression + MYC overexpression
BCL2 expression + MYC expression
MYC translocation + BCL2 translocation
MYC positive + BCL2 positive
MYC expression + BCL2 expression
BCL2 rearrangement + MYC amplification
CD20 positive
CD20 overexpression
CD20 negative
CD20 underexpression
CD20 expression
CXCR4 mutation
CXCR4 R338X
CXCR4 H350fs*
CXCR4 G336X
CXCR4 L326fs*
CXCR4 T318fs*
CXCR4 K327fs*
CXCR4 S338X
CXCR4 S347fs*
MYC rearrangement + BCL2 rearrangement + BCL6 rearrangement
MYC positive + BCL2 positive + BCL6 positive
MYC translocation + BCL6 translocation + BCL2 translocation
MYC rearrangement + BCL6 rearrangement
MYC translocation + BCL6 translocation
PD-L1 overexpression
PD-L1 expression
PD-L1 underexpression
PD-L1 amplification
PD-L1 elevation
TNFRSF8 positive
MYC rearrangement
TNFRSF8 expression
TNFRSF8 negative
MYC positive
MYC negative
MYC mutation
MYC expression
MYC translocation
MYC overexpression
CD19 positive
BCL2 positive
BCL2 overexpression
BCL2 expression
CD19 expression
BCL2 rearrangement
CD19 underexpression
BCL2 mutation
BCL2 F104I
CD19 mutation
BCL2 amplification
MYD88 L265P
MYD88 mutation
MYD88 wild-type
LDH elevation
TMB-L
TMB-H
LDH-L
BIRC3 mutation
IGH mutation
CD20 positive + TMB-L
ABCB1 2677G>T/W
VEGFA 2055A>C
ABCB1 mutation + VEGFA mutation
CCR7 positive
BCL6 rearrangement
BCL6 translocation
BCL6 positive
VEGFA 1154G/A
CCR7 overexpression
CD79B mutation
CD79B mutation
RHOA mutation
RHOA G17V
CXCL12 overexpression
KIR3DL2 Q386E
KIR3DL2 C336R
PIM1 overexpression
Chr t(2;5)(p23;q35) NPM1/ALK
IL2RA-L
CCL19 overexpression
CCL19 elevation
CXCL12 expression
PIM1 mutation
NPM1-ALK fusion
IL2RA expression
NPM1-ALK F1174C
NPM1-ALK L1196Q
NPM1-ALK I1171T
NPM1-ALK I1171N
IL2RA elevation
NPM-ALK fusion
IL2RA positive
CD79B expression
EZH2 mutation
RGL1 overexpression
CD70 expression
BTK C481
BTLA overexpression
CRTAM overexpression
PD-1 overexpression
MYD88 mutation + CXCR4 mutation
NPM1-NR4A3 fusion
SEPTIN6-TRIM33 fusion
CD79A mutation
IDH2 mutation
PD-L1 amplification + LAG3 overexpression
PD-L1 amplification + HLA-DRA overexpression
PD-L1 amplification + CD3D overexpression
MYD88 mutation + PRDM15 expression
MYD88 mutation + TNIK expression
MYD88 mutation + GPER1 expression
MYD88 mutation + DUSP22 expression
MYD88 mutation + WNK2 expression
MRD4 negative
EZH2 mutation + BCL2 translocation
BCL6 fusion + NOTCH2 mutation
LMO2 overexpression
BIRC5 expression
CD19 expression + TNFRSF17 expression
CCND1 overexpression
PAX5 overexpression
IL10-L
TNFA-L
CCL20-L
TBX21 overexpression
CD37 expression
FOXP1 overexpression
ICOS underexpression
RPS6 underexpression
CDCA2 overexpression
ITK overexpression
CTLA4 overexpression
SOX11 expression
HES1 overexpression
H1-4 overexpression
MYD88 L265P + CD79B mutation
ATM mutation
CCND2 overexpression
CXCR4 S338X + TP53 R196X
TP53 T175H + PIK3CA H1047R
MYD88 L265P + BRAF V600E
CLTC-ALK fusion
TP53 mutation + MET amplification + PD-L1 overexpression
CD38 expression
NOTCH2 mutation + NCOA4 mutation + PTEN mutation + EPHA3 mutation + KMT2D mutation
VAV1 mutation
LAG3 overexpression
IKZF1 deletion + IKZF3 deletion
BCR-ABL1 T315I
MYC amplification + BCL2 amplification + TNFRSF8 expression
FCGR2A mutation
BIRC3-MALT1 fusion
CD34 underexpression
LRP1B mutation
TP53 mutation + CARD11 mutation + SMARCA4 mutation
CD20 expression + PAX5 expression + BCL2 expression
CREBBP mutation
EP300 mutation
TSC2 mutation
IFNG-L
GNA12 mutation
IL2-L
CTSS Y132D
GNA13 mutation
SOCS1 mutation
TIGIT overexpression
HAVCR2 expression
KLHL14 mutation
CD24 overexpression
LEF1 overexpression
TBX21 expression
CD38 positive
BTK C481S
MYD88 L265P + CXCR4 mutation
EP300 overexpression
ATM deletion
IL2 elevation
EZH2 Y646F
IL10 elevation
TNFA elevation
ATM underexpression
EZH2 Y641
CCND1 expression
BCL2 fusion + EZH2 mutation
CD70 overexpression
Chr t(2;17)(p23;q23) CLTC/ALK
EZH2 A682G
PAX5 mutation
EZH2 overexpression
PD-1 elevation
Chr del(17p)
Chr del(11q)
Chr del(6q)(q15)
CD5 gene expression signature
Chr t(11;14)
Chr del(17)(p13.1)
Chr del(11)(q22.3)
BCL2 overexpression + MCL1 overexpression
BCL2 overexpression + MCL1 expression
miR-193b-5p expression
IL6 elevation
ARID1B mutation
SRC overexpression
JAK2 overexpression
LCK overexpression
LY9 expression
FCGR2B expression
CD28 expression
PLK4 expression
PIK3CG expression
PIK3CD expression
PIK3CB expression
PIK3CA expression
miR-1244 expression
BCL2L1 overexpression
CXCL11 elevation
BCL2L11 deletion
miR-6840-3p expression
MCL1 expression
MAD2L2 overexpression
MYC rearrangement + LDH elevation
ALK negative + TP53 deletion
CCDC86 expression + NPM1 expression
CD22 positive
MELK overexpression
CXCL8 elevation
CCL4 elevation
IL27 elevation
TNFAIP3 mutation
miR-1244 overexpression + miR-193-5p overexpression
AP2M1 overexpression
BCL2 positive + LGALS3 expression
B2M mutation
BACH2 overexpression
TET2 mutation
REL overexpression
DNMT3A mutation
CDKN2B deletion
CDKN2A deletion
NOTCH1 mutation
SLC1A5 overexpression
KMT2D mutation
BTK expression + MYC expression
miR-6860-5p expression
DLGAP2 deletion
ARID1B deletion
CCND1 expression + CDK4 expression
IRF8 mutation
BTK expression + BCL2 expression + MYC expression
BTK expression + BCL2 expression
TERT amplification
CDK2 amplification
CDK4 amplification
PRDM1 mutation
MDM2 amplification
CARD11 mutation
CD163 elevation
PDK4 overexpression
IRF4 mutation
CD5 positive
XPO1 E571K
TP53 mutation + BCL2 rearrangement
SAMHD1 mutation
ROR1 overexpression
CDKN2A deletion + MTAP deletion
ARID1A mutation
TP53 mutation + ARID1A mutation
PRMT5 overexpression + MTAP deletion
miR-182-5p expression
CD5 overexpression
Albumin-L
SETD1B overexpression
INO80 overexpression
SETD2 overexpression
KMT2C overexpression
NCOR1 overexpression
CHD8 overexpression
ARID1B overexpression
SETD5 overexpression
SMARCA4 overexpression
TP53 overexpression + CD5 overexpression
FTL elevation
NOTCH2 mutation
MYC expression + PAICS expression
PPM1D mutation
NRAS G13D
CD58 mutation
LDH elevation + TP53 mutation
MUC20 underexpression
miR-885-3p expression
CDKN2A overexpression
RB1 deletion
KLHL6 expression
BRCA mutation
IKZF1 G151A overexpression
IKZF3 G152A overexpression
MCL1 overexpression
NLRC5 mutation
PAK1 overexpression
miR-199a-5p expression
BCL7A mutation
BCL2 elevation + IGH elevation
MALT1 overexpression
miR-20b-5p expression
CD19 positive + CD20 positive
PTPN6 negative
miR-1231 expression
MYC expression + MCL1 expression
FAS mutation
PTEN deletion + BCL2 translocation
miR-155 overexpression
BCL2L2 overexpression
ROR1 expression
PLCG2 mutation
TNFSF13B negative
CD40L negative
CD79B mutation + TNFAIP3 mutation
HRD